In the company’s news yesterday,
Kraig Biocraft Laboratories, Inc. announced that Dr. Fraser’s team has “made significant progress on developing enzymes and strategies for conducting site specific genetic recombination in silkworm.”
“In the Company’s view, the development of this particular gene splicing technology is the key to unlocking the tremendous commercial potential of spider silks and other recombinant polymers,” stated Kraig’s CEO, Kim K. Thompson. “Dr. Fraser’s report of this news from the laboratory is the culmination of years of scientific effort. It is a huge milestone on the path to commercialization,” continued Thompson.
“We believe that we are the only people who have this capability at this time.” Dr. Fraser added.
Dr. Fraser’s team of research scientists, working within University of Notre Dame laboratories, has made several significant advancements over the last four or five months. This most recent announcement follows shortly after the company’s report that it had performed approximately five thousand genetic insertions, and that it had achieved the activation of fluorescent marker gene sequences which the researchers incorporated into spider silk DNA packets.
Site specific genetic recombination allows for the genetic targeting of a specific location on a specific chromosome. This ability is potentially vital to the company’s work because of the strong influence of what geneticists call “location effects.” These effects do not result from the coding of a specific gene, but from the location of that gene on a specific chromosome.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
